iRhythm Technologies, Inc.

NasdaqGS IRTC

iRhythm Technologies, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -20.34%

iRhythm Technologies, Inc. EBITDA Margin is -20.34% for the Trailing 12 Months (TTM) ending September 30, 2024, a -20.01% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

iRhythm Technologies, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -16.95%, a 41.45% change year over year.
iRhythm Technologies, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -28.95%, a -42.07% change year over year.
iRhythm Technologies, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -20.37%, a -24.22% change year over year.
iRhythm Technologies, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -16.40%, a 18.69% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqGS: IRTC

iRhythm Technologies, Inc.

CEO	Mr. Quentin S. Blackford
IPO Date	Oct. 20, 2016
Location	United States
Headquarters	699 8th Street
Employees	2,000
Sector	Health Care
Industries Telehealth Internet of Things (IoT) Medical Instruments

Description

iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Key trends

Past 5 years